Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity.
about
Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature ReviewCognitive remission: a novel objective for the treatment of major depression?Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewThe antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes.The current role of thiazolidinediones in diabetes management.Dicholine succinate, the neuronal insulin sensitizer, normalizes behavior, REM sleep, hippocampal pGSK3 beta and mRNAs of NMDA receptor subunits in mouse models of depression.Cardiometabolic Health in Bipolar DisorderPPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: possible role of insulin-like growth factor 2.Pioglitazone could induce remission in major depression: a meta-analysisPioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitusLong-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's diseaseTreatment with Rhodiola crenulata root extract ameliorates insulin resistance in fructose-fed rats by modulating sarcolemmal and intracellular fatty acid translocase/CD36 redistribution in skeletal muscle.Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.A Possible Role for Pioglitazone in the Management of Depressive Symptoms in Metabolic Syndrome Patients (EPICAMP Study): A Double Blind, Randomized Clinical Trial.Epigenetic differences in monozygotic twins discordant for major depressive disorderAdjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response.Metabolic disturbances connecting obesity and depression.Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice.Metabolic syndrome and major depression.Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Hippocampal gene expression of deiodinases 2 and 3 and effects of 3,5-diiodo-L-thyronine T2 in mouse depression paradigms.Drug repurposing may generate novel approaches to treating depression.Therapeutic strategies for treatment of inflammation-related depression.Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial.NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice.Cross-species evidence from human and rat brain transcriptome for growth factor signaling pathway dysregulation in major depressionBirth weight and catch up growth are associated with childhood impulsivity in two independent cohorts
P2860
Q26771735-4B2D905D-1851-4128-A1B4-7B9727702BDDQ26775386-D54EADAE-25A7-464D-9C39-54C68F52CD24Q26782993-5801B26A-29B9-41A1-B786-F39F0D6F3F60Q27303048-28DA8674-D312-4BBE-9FAA-9183CF185FB6Q30250347-EE6AFF4B-7F14-48DA-A63E-E41F1DDC1250Q30621713-B1AE2C54-0D3B-4C4E-9D91-42D890A642E4Q33795131-E43754E2-58F6-49EE-BA40-E2E7EC824FB5Q33960389-0250917A-89EC-46A7-9462-D9979AFBCFDFQ34417848-B4736F72-E042-4249-9D20-AD12B7C2867AQ34548227-14D0335F-4A13-4376-BB55-171FB60E1B15Q35942767-0667B967-D48B-493A-BC0C-CB22B627EC7BQ36044265-A42E66E9-42ED-4BD0-97C3-EAD44FCF6B26Q36074116-E80D3DFD-AF81-40CC-A5E3-1C96B813D875Q36100305-75B2F4B0-E9ED-4546-AEE9-D387817CE27AQ36980014-4E9C14BC-2C78-43C3-80E0-1B30E89ECE0FQ37061840-47E8D3D0-BF3F-4AF5-8AE0-148D1F28EFCCQ37161489-D68C51C4-6217-419C-852E-F10FBF2EB5ECQ37217434-8C3B7773-95A6-4B76-81AF-EDE67F0B2EFAQ37486869-ACB05BE1-11A0-4E67-B9D3-60E4334D2322Q38150605-5BFBE61A-928D-46A0-BC2B-0330FABAFBEFQ38157027-A0B19EA6-2C16-437E-9322-82BE1C506820Q38641190-D855C32E-187A-49C4-BF3E-5ACCA6C71F95Q39215827-94725479-110B-4BD3-B2CF-7366757D2A74Q47765380-F59344FB-60E6-47DE-A989-D43E5FF51FF2Q47785792-2D1F42E6-F21E-4620-A5FD-07BDCBB8F476Q48128615-33F80CF6-5F79-4FA0-B533-695F09DC3744Q48689485-93709319-D0AC-42ED-89ED-0275E03B7156Q56337964-5969488B-9976-4CD0-B5DD-7AA13FB7F91DQ58747352-0C8C8236-CB03-4ACF-8611-96AA95813D62
P2860
Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Use of insulin sensitizers for ...... ompanied by abdominal obesity.
@ast
Use of insulin sensitizers for ...... ompanied by abdominal obesity.
@en
type
label
Use of insulin sensitizers for ...... ompanied by abdominal obesity.
@ast
Use of insulin sensitizers for ...... ompanied by abdominal obesity.
@en
prefLabel
Use of insulin sensitizers for ...... ompanied by abdominal obesity.
@ast
Use of insulin sensitizers for ...... ompanied by abdominal obesity.
@en
P2093
P2860
P1476
Use of insulin sensitizers for ...... ompanied by abdominal obesity.
@en
P2093
Carla Conroy
David E Kemp
Elizabeth Fein
Faramarz Ismail-Beigi
Joseph R Calabrese
Keming Gao
Robert L Findling
Sarah Obral
Stephen J Ganocy
P2860
P304
P356
10.1016/J.JAD.2011.06.033
P577
2011-07-22T00:00:00Z